Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Maurizio Zangari to Chromosomes, Human, Pair 1

This is a "connection" page, showing publications Maurizio Zangari has written about Chromosomes, Human, Pair 1.

 
Connection Strength
 
 
 
1.359
 
  1. Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, Tian E, van Rhee F, Zangari M. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020 04; 189(1):67-71.
    View in: PubMed
    Score: 0.667
  2. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
    View in: PubMed
    Score: 0.212
  3. Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer J. 2019 08 09; 9(8):62.
    View in: PubMed
    Score: 0.163
  4. Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 2015 Jun 11; 125(24):3756-9.
    View in: PubMed
    Score: 0.121
  5. Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood. 2014 Apr 17; 123(16):2504-12.
    View in: PubMed
    Score: 0.111
  6. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.067
  7. Shaughnessy JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007 Jun; 137(6):530-6.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.